Description

Product Description

EPO Mimetic Peptide-1 (EMP-1) is a 20-amino-acid peptide that mimics the biological effects of erythropoietin (EPO) by binding to and activating the erythropoietin receptor (EPOR). Unlike recombinant erythropoietin, which is a large glycoprotein hormone, EMP-1 is a much smaller peptide that offers advantages in synthesis, stability, and molecular manipulation, making it an ideal agent for fundamental and translational hematopoietic studies.

EPO plays a central role in erythropoiesis by promoting the survival, proliferation, and differentiation of erythroid progenitor cells in the bone marrow. EMP-1 mimics these effects, acting as a potent stimulator of erythropoietic signaling cascades in vitro and in vivo.

Research Background

The discovery of EMP-1 was driven by efforts to design small, bioactive peptide mimetics of erythropoietin that could selectively activate EPOR without the complexity of the native glycoprotein. EMP-1 binds to the extracellular domain of EPOR and induces receptor dimerization, which triggers downstream phosphorylation cascades leading to the activation of JAK2/STAT5, PI3K/AKT, and MAPK pathways.

This receptor activation enhances erythroid progenitor proliferation and delays apoptosis, ultimately leading to an increased number of mature erythrocytes. EMP-1 has been demonstrated to increase reticulocyte counts in preclinical models and is considered a prototype molecule for the development of next-generation erythropoiesis-stimulating agents (ESAs).

Key Research Features

• Erythropoietin Receptor Activation – Mimics endogenous EPO by binding EPOR and activating JAK2/STAT5 signaling.

• Cell Proliferation Enhancement – Stimulates erythroid progenitor cell proliferation in vitro.

• In Vivo Reticulocyte Induction – Promotes reticulocytosis and increases red cell mass.

• Non-Glycosylated Peptide Form – Simplifies synthesis and ensures chemical stability.

• Mechanistic Research Tool – Ideal for studying EPOR signaling and erythroid differentiation.

Research Applications

• Hematopoiesis and erythroid differentiation studies

• Development of erythropoietin mimetics and ESAs

• JAK2/STAT5 pathway investigation

• Cell survival and apoptosis regulation studies

• Preclinical anemia and hypoxia models

EPO Mimetic Peptide-1 offers a stable and bioactive research alternative to recombinant erythropoietin, allowing for deeper mechanistic exploration of red blood cell development and related disease models.

Product Specifications

Mechanism of Action

EPO Mimetic Peptide-1 functions by directly engaging the erythropoietin receptor (EPOR), mimicking the natural ligand EPO. This interaction promotes receptor dimerization, leading to the activation of downstream kinases and transcription factors that regulate erythroid lineage commitment.

1. EPOR Activation
   EMP-1 binds to the extracellular domain of EPOR, initiating receptor dimerization and activation.

2. JAK2/STAT5 Pathway
   The receptor-associated JAK2 kinase becomes phosphorylated and subsequently activates STAT5, a transcription factor that regulates erythroid gene expression.

3. PI3K/AKT and MAPK Pathways
   Secondary signaling cascades promote cell cycle progression, survival, and metabolic activity within erythroid progenitors.

4. Functional Outcome
   The net result is increased erythroid cell proliferation, reduced apoptosis, and elevated reticulocyte output, mirroring the effects of erythropoietin.

This makes EMP-1 a versatile and scalable peptide model for studying erythropoietic regulation and red blood cell biology.

Side Effects

Although EPO Mimetic Peptide-1 is primarily for research use, potential biological responses observed in models include:

• Hematological Changes – Excessive erythroid proliferation or polycythemia at high concentrations.

• Cardiovascular Stress – Elevated hematocrit may impact vascular resistance in vivo models.

• Cellular Adaptation – Long-term exposure can desensitize EPOR signaling.

• Off-Target Signaling – Possible cross-activation of cytokine-related pathways under certain conditions.

Researchers should apply controlled dosing and appropriate in vitro/in vivo experimental designs to ensure reproducibility and accuracy.

Disclaimer

For research use only. Not for human or veterinary use. Not intended for diagnostic or therapeutic purposes.

Keywords

EPO mimetic peptide-1, EMP-1, erythropoietin receptor agonist, EPOR peptide, hematopoiesis research, anemia model, JAK2/STAT5 signaling, red blood cell differentiation, CAS 186526-28-3, erythropoietin mimetic compound

Shipping Guarantee

All products are shipped with tax-inclusive clearance, full cold-chain protection, and loss/damage insurance.

Transaction Guarantee

We accept T/T, PayPal, and cryptocurrency. Secure global delivery with professional documentation support.